Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BBIO – BridgeBio Pharma, Inc.

Float Short %

11.43

Margin Of Safety %

Put/Call OI Ratio

0.44

EPS Next Q Diff

0.24

EPS Last/This Y

0.29

EPS This/Next Y

1.01

Price

49.1

Target Price

63.5

Analyst Recom

1.23

Performance Q

48.86

Relative Volume

0.52

Beta

1.25

Ticker: BBIO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25BBIO46.290.520.7677170
2025-07-28BBIO46.240.520.1777390
2025-07-29BBIO46.30.511.3879365
2025-07-30BBIO45.610.510.3979519
2025-07-31BBIO47.240.510.0680136
2025-08-01BBIO47.390.501.1881520
2025-08-04BBIO47.750.531.2186498
2025-08-05BBIO49.220.540.2387930
2025-08-06BBIO44.690.521.4592757
2025-08-07BBIO45.920.470.2490473
2025-08-08BBIO46.610.461.5190398
2025-08-11BBIO48.250.452.7589674
2025-08-12BBIO49.090.481.9291327
2025-08-13BBIO50.40.500.0492999
2025-08-14BBIO51.170.510.2392491
2025-08-15BBIO51.320.510.2793030
2025-08-18BBIO49.020.430.6572328
2025-08-19BBIO48.920.440.2572919
2025-08-20BBIO48.850.440.4272846
2025-08-21BBIO50.250.440.7073029
2025-08-22BBIO49.110.440.2373239
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25BBIO46.3058.3123.3-2.47
2025-07-28BBIO46.1639.9129.6-2.60
2025-07-29BBIO46.3239.9127.8-2.60
2025-07-30BBIO45.6239.9134.0-2.60
2025-07-31BBIO47.2739.9115.0-2.60
2025-08-01BBIO47.3739.9127.8-2.60
2025-08-04BBIO47.7539.9125.7-2.60
2025-08-05BBIO49.2139.9117.1-2.60
2025-08-06BBIO44.6939.9163.0-2.60
2025-08-07BBIO45.9539.9210.2-2.60
2025-08-08BBIO46.5832.9182.4-2.99
2025-08-11BBIO48.2432.9217.2-2.99
2025-08-12BBIO49.1032.9223.9-2.67
2025-08-13BBIO50.3832.9220.7-2.67
2025-08-14BBIO51.1739.2224.6-2.59
2025-08-15BBIO51.3139.2229.5-2.59
2025-08-18BBIO49.0239.2247.4-2.59
2025-08-19BBIO48.9139.2231.3-2.59
2025-08-20BBIO49.2239.2228.2-2.59
2025-08-21BBIO50.2339.2220.2-2.59
2025-08-22BBIO49.1039.2239.0-2.59
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25BBIO-40.743.2812.11
2025-07-28BBIO-40.743.1912.11
2025-07-29BBIO-40.743.1912.11
2025-07-30BBIO-40.743.1912.11
2025-07-31BBIO-39.923.1912.11
2025-08-01BBIO-35.853.1912.11
2025-08-04BBIO-35.853.1612.11
2025-08-05BBIO-35.853.1612.11
2025-08-06BBIO-35.853.1612.11
2025-08-07BBIO-35.723.1612.11
2025-08-08BBIO-35.723.1612.02
2025-08-11BBIO-35.724.4512.02
2025-08-12BBIO-35.834.4511.44
2025-08-13BBIO-36.254.4511.44
2025-08-14BBIO-36.254.4511.44
2025-08-15BBIO-36.314.4511.43
2025-08-18BBIO-36.313.6111.43
2025-08-19BBIO-36.343.6111.43
2025-08-20BBIO-36.323.6111.43
2025-08-21BBIO-36.323.6111.43
2025-08-22BBIO-36.353.6111.43
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.95

Avg. EPS Est. Current Quarter

-0.65

Avg. EPS Est. Next Quarter

-0.71

Insider Transactions

-36.35

Institutional Transactions

3.61

Beta

1.25

Average Sales Estimate Current Quarter

109

Average Sales Estimate Next Quarter

127

Fair Value

Quality Score

23

Growth Score

50

Sentiment Score

97

Actual DrawDown %

33.2

Max Drawdown 5-Year %

-92.8

Target Price

63.5

P/E

Forward P/E

PEG

P/S

39.79

P/B

P/Free Cash Flow

EPS

-4.09

Average EPS Est. Cur. Y​

-2.59

EPS Next Y. (Est.)

-1.58

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-329.25

Relative Volume

0.52

Return on Equity vs Sector %

18.7

Return on Equity vs Industry %

31.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.37

EBIT Estimation

239
BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 725
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
stock quote shares BBIO – BridgeBio Pharma, Inc. Stock Price stock today
news today BBIO – BridgeBio Pharma, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BBIO – BridgeBio Pharma, Inc. yahoo finance google finance
stock history BBIO – BridgeBio Pharma, Inc. invest stock market
stock prices BBIO premarket after hours
ticker BBIO fair value insiders trading